Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial)

Lignende værker

• Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group
  af: Adès, Lionel, et al.
  Udgivet: (2018)
• Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
  af: Kayser, Sabine, et al.
  Udgivet: (2020)
• A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM)
  af: Ades, Lionel, et al.
  Udgivet: (2019)
• Exome analysis of treatment-related AML after APL suggests secondary evolution
  af: Wang, Tianjiao, et al.
  Udgivet: (2018)
• Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL)
  af: Damery, Erin, et al.
  Udgivet: (2016)